[The use of fludarabine phosphate (Fludara) to treat chronic B-cell lymphocytic leukemia and non-Hodgkin's lymphoma resistant to standard chemotherapy].

Abstract

Following monochemotherapy with fludarabin phosphate (fludara), complete (18%), and partial remission (27%) with stabilization (45%) was recorded in patients with B-cell chronic lymphocytic leukemia, most of whom were resistant to alkylating cytostatic drugs and their combinations containing anthracyclines. Long-term remission was registered in patients with low and moderate grade non-Hodgkin's lymphoma, resistant to standard cytostatic treatment, due to the therapeutic synergism of fludara and cytosinarabinoside (FAVAMP).

• Authors: M L Gershanovich, A Iu Zaritskiĭ, N V Medvedeva, K M Abdulkadyrov, I G Samuskevich, I A Beresneva
• Journal: Voprosy onkologii (Vopr Onkol) Vol. 44 Issue 6 Pg. 696-700 ( 1998) ISSN: 0507-3758 [Print] Russia (Federation)
• Vernacular Title: Fludarabina fosfat (Fludara) v lechenii reziztentnykh k standartnoĭ khimioterapii bol'nykh B-kletochnym khronicheskim limfoleĭkozom i nekhodzhkinskimi limfomami.
• PMID: 10087967 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Antimetabolites, Antineoplastic
• Vidarabine Phosphate
• fludarabine phosphate

Topics

• Adult
• Aged
• Antimetabolites, Antineoplastic (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Drug Resistance, Neoplasm
• Female
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)
• Lymphoma, Non-Hodgkin (drug therapy)
• Male
• Middle Aged
• Treatment Outcome
• Vidarabine Phosphate (analogs & derivatives, therapeutic use)